When was Interpace Biosciences founded?

Interpace Biosciences was founded in 1986 and raised its 1st funding round 31 years after it was founded.

Where is Interpace Biosciences located?

Interpace Biosciences is headquartered in Parsippany Troy Hills, United States.

How many employees does Interpace Biosciences have?

As of Sep 30, 2026, the latest employee count at Interpace Biosciences is 119.

Is Interpace Biosciences a funded company?

Interpace Biosciences is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Jan 20, 2017.

When was the latest funding round of Interpace Biosciences?

Interpace Biosciences' latest funding was a $***** Post IPO round on Oct 11, 2024, with participation from 0 investor.

What is the annual revenue of Interpace Biosciences?

Annual revenue of Interpace Biosciences is between $10M and $50M as on Dec 31, 2025

Where does Interpace Biosciences rank among its competitors?

Interpace Biosciences ranks 49th amongst 886 active competitors, of which 178 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Guardant Health, which secured $350M in Nov, 2025.

Who are the top competitors of Interpace Biosciences?

Interpace Biosciences' top competitors include Natera, Guardant Health and Foundation Medicine. Among them, Guardant Health secured the most recent funding round in November, 2025.

Interpace Biosciences - 2026 Company Profile, Funding, Competitors & Financials

Interpace Biosciences is a public company based in Parsippany Troy Hills (United States), founded in 1986. It operates as a Provider of molecular diagnostic tests and pathology services for cancer diagnosis. Interpace Biosciences has raised an undisclosed amount in funding. The company has 886 active competitors, including 178 funded and 141 that have exited. Its top competitors include companies like Natera, Guardant Health and Foundation Medicine.

Company Details

Provider of molecular diagnostic tests and pathology services for cancer diagnosis. It offers molecular analysis for early cancer diagnosis and treatment. The company provides clinically beneficial, evidence-based molecular diagnostic tests and pathology services.

Website: www.interpace.com/
Social
Email ID: *****@Interpace.com
Phone Number: +1 **********

Key Metrics

Founded Year

1986

Location

Parsippany Troy Hills, United States

Stage

Public

Latest Funding Round

Post IPO, Oct 11, 2024, $*****

Investors

CYwP Funds & 3 more

Ranked

49^th among 886 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2025

Employee Count

119 as on Sep 30, 2026

Similar Companies

Natera & 584 more

Exit Details

Public

View Interpace Biosciences' full profile

Interpace Biosciences is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Interpace Biosciences, Inc. CIN: 1054102 , United States, Active		$10M - $50M (As on Dec 31, 2025)	-	-
Interpace Biosciences, Inc. CIN: 22-2919486 , United States, Active	Dec 31, 1985	-	94 (As on Feb 28, 2023)	-

Interpace Biosciences got listed on May 22, 1998.

Click here to take a look at Interpace Biosciences's IPO in detail

Interpace Biosciences has raised funding over 4 rounds. Its first funding round was on Jan 20, 2017. Interpace Biosciences has 4 institutional investors.

Here is the list of recent funding rounds of Interpace Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 11, 2024	2655906	Post IPO	3402479	6794048	8058324	8914877
Jan 27, 2020	1841314	Post IPO	6019658	3004215	2543387	1315 Capital & 1 more
Oct 12, 2017	3208118	Post IPO	2086010	5918277	6796710	7122215

Access funding benchmarks and valuations. Sign up today!

View details of Interpace Biosciences's funding rounds and investors

Interpace Biosciences' employee count trend

Interpace Biosciences has 119 employees as of Sep 26. Here is Interpace Biosciences's employee count trend over the years:

Employee count trend for Interpace Biosciences

Uncover Interpace Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Interpace Biosciences include Natera, Guardant Health and Foundation Medicine. Here is the list of Top 10 competitors of Interpace Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Bain Capital Life Sciences ... & 18 others	80/100
2nd	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	SoftBank Vision Fund, Lightspeed Venture Partners ... & 25 others	79/100
3rd	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Redmile Group, Deerfield & 11 others	70/100
4th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, SoftBank Group & 11 others	70/100
5th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Apis Partners, Beyond Ventures & 22 others	69/100
6th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
7th	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	68/100
8th	Hologic 1985, Marlborough (United States), Acquired	Manufacturer of medical diagnostic devices and systems for women health	-	Saints Capital, Triodos Investment Management ... & 3 others	67/100
9th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	66/100
10th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Bluebird Ventures & 6 others	66/100
49th	Interpace Biosciences 1986, Parsippany Troy Hills (United States), Public	Provider of molecular diagnostic tests and pathology services for cancer diagnosis	-	CYwP Funds, 1315 Capital & 2 others	50/100